Tania Gudu1, Adrien Etcheto2, Maarten de Wit3, Turid Heiberg4, Mara Maccarone5, Andra Balanescu6, Peter V Balint7, Dora S Niedermayer7, Juan D Cañete8, Philip Helliwell9, Umut Kalyoncu10, Uta Kiltz11, Kati Otsa12, Douglas J Veale13, Kurt de Vlam14, Rossana Scrivo15, Tanja Stamm16, Tore K Kvien17, Laure Gossec18. 1. Department of Rheumatology, Sorbonne universités, UPMC université Paris 06, institut Pierre-Louis d'épidémiologie et de santé publique, GRC-UPMC 08 (EEMOIS), Pitié-Salpêtrière Hospital, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France; Research Center of Rheumatic Diseases, University of Medicine and Pharmacy Carol Davila, St Maria Hospital, 011172 Bucharest, Romania. 2. Epidemiology and Biostatistics Unit, Sorbonne Paris Cité Research Center, Inserm U1153, 75014 Paris, France. 3. Patient Research Partner, People with Arthritis/Rheumatism in Europe (PARE), 8802 Zurich, Switzerland. 4. Department of Health and Social Sciences, Østfold University College, Halden, Regional Research Support, Oslo University Hospital, 4950 Oslo, Norway. 5. Patient Research Partner, ADIPSO (Associazione per la Difesa degli Psoriasici)-PE.Pso.POF (Pan European Psoriasis Patients' Organization Forum), 00193 Rome, Italy. 6. Research Center of Rheumatic Diseases, University of Medicine and Pharmacy Carol Davila, St Maria Hospital, 011172 Bucharest, Romania. 7. 3rd Rheumatology Department, National Institute of Rheumatology and Physiotherapy, 1023 Budapest, Hungary. 8. Arthritis Unit, Department of Rheumatology, Hospital Clínic and IDIBAPS, 08036 Barcelona, Spain. 9. Leeds Institute of Rheumatic and Musculoskeletal Medicine, University of Leeds, LS7 4SA Leeds, UK. 10. Division of Rheumatology, Faculty of Medicine, Hacettepe University, 06100 Ankara, Turkey. 11. Rheumazentrum Ruhrgebiet, Herne and Ruhr-Universität Bochum, 44652 Herne, Germany. 12. Rheumatology Department, Tallinn Central Hospital, 10138 Tallinn, Estonia. 13. Dublin Academic Medical Centre, St Vincent's University Hospital, D4 Dublin, Ireland. 14. Department of Rheumatology, University Hospitals Leuven, 3000 Leuven, Belgium. 15. Dipartimento di Medicina Interna e Specialità Mediche, Sapienza Università di Roma, 00185 Rome, Italy. 16. Division of Rheumatology, Department of Medicine 3, Medical University of Vienna, 1090 Vienna, Austria. 17. Department of Rheumatology, Diakonhjemmet Hospital, No-0370 Oslo, Norway. 18. Department of Rheumatology, Sorbonne universités, UPMC université Paris 06, institut Pierre-Louis d'épidémiologie et de santé publique, GRC-UPMC 08 (EEMOIS), Pitié-Salpêtrière Hospital, AP-HP, 47-83, boulevard de l'Hôpital, 75013 Paris, France. Electronic address: laure.gossec@aphp.fr.
Abstract
OBJECTIVES: Fatigue is an aspect of psoriatic arthritis (PsA), which is important to patients. The objective was to evaluate magnitude of fatigue in PsA patients and to assess factors that might explain high levels of fatigue. METHODS: This was an ancillary analysis of a cross-sectional study in 13 countries of unselected PsA patients who fulfilled the CASPAR criteria. Patient-perceived importance of fatigue was assessed through a priority exercise. Levels of fatigue were assessed by a numeric rating scale (range 0-10). Factors potentially associated with fatigue>5/10: i.e., demographic variables (age, gender, disease duration, education level) and disease related characteristics including joint counts, C-reactive protein, skin psoriasis, axial involvement, enthesitis, dactylitis, structural damage, were assessed by univariate, multivariate logistic and multiple linear regression. RESULTS: In all, 246 patients were analysed: mean±standard deviation age 51.2±13.0years, mean disease duration 9.9±10.1years, mean DAS28 3.5±1.3. Fatigue was ranked second in patient-perceived importance, after pain. Magnitude of fatigue was high: mean fatigue 5.0±3.0. Fatigue>5/10 was well explained (variance explained 73%) by skin psoriasis (odds ratio 4.67 [95% confidence interval 1.05; 20.72]), tender joints (1.30 [1.01; 1.68]) and lower education level (1.09 [1.02; 1.23]). In the multiple linear regression model, fatigue was explained by skin psoriasis, tender joints, enthesitis, female gender, education level. CONCLUSIONS: Fatigue is a priority for PsA patients. Fatigue levels were high in these patients and fatigue>5/10 was mainly associated with disease-related factors but also patient-related variables, indicating that the etiology of fatigue in PsA is multifactorial.
OBJECTIVES:Fatigue is an aspect of psoriatic arthritis (PsA), which is important to patients. The objective was to evaluate magnitude of fatigue in PsA patients and to assess factors that might explain high levels of fatigue. METHODS: This was an ancillary analysis of a cross-sectional study in 13 countries of unselected PsA patients who fulfilled the CASPAR criteria. Patient-perceived importance of fatigue was assessed through a priority exercise. Levels of fatigue were assessed by a numeric rating scale (range 0-10). Factors potentially associated with fatigue>5/10: i.e., demographic variables (age, gender, disease duration, education level) and disease related characteristics including joint counts, C-reactive protein, skin psoriasis, axial involvement, enthesitis, dactylitis, structural damage, were assessed by univariate, multivariate logistic and multiple linear regression. RESULTS: In all, 246 patients were analysed: mean±standard deviation age 51.2±13.0years, mean disease duration 9.9±10.1years, mean DAS28 3.5±1.3. Fatigue was ranked second in patient-perceived importance, after pain. Magnitude of fatigue was high: mean fatigue 5.0±3.0. Fatigue>5/10 was well explained (variance explained 73%) by skin psoriasis (odds ratio 4.67 [95% confidence interval 1.05; 20.72]), tender joints (1.30 [1.01; 1.68]) and lower education level (1.09 [1.02; 1.23]). In the multiple linear regression model, fatigue was explained by skin psoriasis, tender joints, enthesitis, female gender, education level. CONCLUSIONS:Fatigue is a priority for PsA patients. Fatigue levels were high in these patients and fatigue>5/10 was mainly associated with disease-related factors but also patient-related variables, indicating that the etiology of fatigue in PsA is multifactorial.
Authors: Marco Garrido-Cumbrera; Ottfrid Hillmann; Raj Mahapatra; David Trigos; Petra Zajc; Luisa Weiss; Galya Bostynets; Laure Gossec; Laura C Coates Journal: Rheumatol Ther Date: 2017-06-09
Authors: Ana-Maria Orbai; Maarten de Wit; Philip J Mease; Kristina Callis Duffin; Musaab Elmamoun; William Tillett; Willemina Campbell; Oliver FitzGerald; Dafna D Gladman; Niti Goel; Laure Gossec; Pil Hoejgaard; Ying Ying Leung; Chris Lindsay; Vibeke Strand; Désirée M van der Heijde; Bev Shea; Robin Christensen; Laura Coates; Lihi Eder; Neil McHugh; Umut Kalyoncu; Ingrid Steinkoenig; Alexis Ogdie Journal: J Rheumatol Date: 2017-02-01 Impact factor: 4.666
Authors: Proton Rahman; Philip J Mease; Philip S Helliwell; Atul Deodhar; Laure Gossec; Arthur Kavanaugh; Alexa P Kollmeier; Elizabeth C Hsia; Bei Zhou; Xiwu Lin; May Shawi; Chetan S Karyekar; Chenglong Han Journal: Arthritis Res Ther Date: 2021-07-14 Impact factor: 5.156